CA-19-9 (Cancer Antigen 19-9) is the most common serum tumor marker used for pancreatic ductal adenocarcinoma, which is expressed in pancreatic and hepatobiliary disease. In symptomatic patients, it can help confirm the diagnosis and aid in assessing the prognosis and predicting the likelihood of recurrence after resection.
CA-125 (Cancer antigen 125) is a tumor marker for ovarian carcinoma. It is used to see if treatment is working or to see if cancer has come back after one has finished treatment.
AFP (Alpha-fetoprotein) is a tumor marker for liver cancer or hepatoma. Is also market for cancer of the ovaries and testes. Used to diagnose liver cancer, find out if cancer has spread (the stage of cancer), and to see if cancer treatment is working, and predict chances of recovery.
Carcinoembryonic antigen (CEA) testing is done for colorectal cancer. The use of CEA testing and CT for follow-up of colorectal cancer patients yields a survival advantage of about 19%.
Prostrate Specific Antigen (PSA) for prostate cancer. “Expert recommendations suggest that prostate cancer survivors should receive annual digital rectal examinations, plus monitoring of prostate-specific antigen levels every 6 months for 5 years, and then annually” ABFM
B2M (Beta 2-microglobulin) is market for multiple myeloma, some lymphomas and leukemia’s. Used to see if cancer treatment is working and to predict chances for recovery.
CA 15-3 and CA 27-29 (Cancer antigens 15-3 and 27-29) are tumor markers for breast cancer. They are used to monitor treatment in women with advanced breast cancer.